Knopp Biosciences, a drug discovery company developing novel treatments for immunological and neurological diseases, announced that it entered the second year of the NIH-funded research to utilize its Kv7 platform to discover and develop non-opioid therapies for the treatment of chronic pain.
The project is funded by the NIH program called Helping to End Addiction Long-term (the NIH HEAL Initiative), which is an aggressive, trans-agency effort to speed scientific solutions to stem the national opioid public health crisis. The grant funding of as much as $8 million is contingent upon the attainment of milestones over five years.
Knopp is advancing a portfolio of selective modulators of Kv7.2/7.3 voltage-gated potassium channels for the treatment of epileptic encephalopathy, neuropathic pain, hearing disorders and ALS.
Read more about Knopp Biosciences here.
Read more about the NIH HEAL Initiative here.
Photo by Polina Tankilevitch from Pexels
